search
Back to results

Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects

Primary Purpose

Erectile Dysfunction

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TPN171H
Sponsored by
Vigonvita Life Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Erectile Dysfunction

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: ≥ 65 years old; Male≥50kg,femal≥45kg, Body mass index should be between 18 and 30 kg/m2 (inclusive); No major organ dysfunction;normal heart, liver and kidney function; Physical examination, vital signs examination, laboratory examination (blood routine, urine routine, blood biochemistry), 12 lead ECG, Abdominal ultrasound, chest X-ray results were normal or abnormal but investigator judged suitable for participating in this trial; Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent Exclusion Criteria: Allergies to test preparations, any of their ingredients, and related preparations; With allergies or allergic diseases; Surgical condition or condition that may significantly affect ADME of the drug, urgical condition or condition that may pose a hazard if the subject participating in the study Myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass grafting, congestive heart failure, severe arrhythmias, cerebrovascular accidents, including transient ischemic attack within 3 months before inclusion; Taken any of drugs(Inhibits or induces liver metabolism) within 2 weeks before inclusion;administered with Nitrate/Nitric oxide (NO) donors。 With a history of the following ocular diseases: nonvascular anterior ischemic optic neuropathy (NAION), abnormal color vision, hereditary retinopathy (e.g. Retinitis pigmentosa), and macular degeneration; A history of sudden decrease or loss of hearing; A history of postural hypotension; Blood loss ≥400 mL within 3 months before inclusion; Participated in other drug clinical trials or medical devices clinical trials within 3 months before administration; Drink alcohol at least 2 times a day or more than 14 times a week in the 6 months prior to enrollment or alcoholics(Drink alcoholics defined as 125 mL of wine, 220 mL of beer, or liquor50mL; Alcoholism is defined as 5 or more drinks in approximately 2 hours) ; A history of drug use or have been screened positive for drug abuse; Smoked more than 10 cigarettes a day within 6 months prior to inclusion; hepatitis B surface antigen (HBsAg),hepatitis C virus antibody,treponema pallidum antibody,Human immunodeficiency virus antibody (HIV)positive; Other factors that the investigator considered inappropriate for the study.

Sites / Locations

  • Shanghai Xuhui Central Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TPN171H

Arm Description

5 mg TPN171H tablets,single dose,oral

Outcomes

Primary Outcome Measures

Adverse events
Number of Participants With treatment-related Adverse Events and Serious Adverse Events
Pharmacokinetic parameter of TPN171H:Tmax
Pharmacokinetic parameter of TPN171H:Tmax
Pharmacokinetic parameter of TPN171H:Cmax
Pharmacokinetic parameter of TPN171H:Cmax
Pharmacokinetic parameter of TPN171H:T1/2
Pharmacokinetic parameter of TPN171H:T1/2
Pharmacokinetic parameter of TPN171H:AUC0-t
Pharmacokinetic parameter of TPN171H:AUC0-t
Pharmacokinetic parameter of TPN171H:AUC0-∞
Pharmacokinetic parameter of TPN171H:AUC0-∞
Pharmacokinetic parameter of TPN171H:AUC0-24h
Pharmacokinetic parameter of TPN171H:AUC0-24h
Pharmacokinetic parameter of TPN171H:Ke
Pharmacokinetic parameter of TPN171H:Ke
Pharmacokinetic parameter of TPN171H:Vd
Pharmacokinetic parameter of TPN171H:Vd
Pharmacokinetic parameter of TPN171H:MRT
Pharmacokinetic parameter of TPN171H:MRT
Pharmacokinetic parameter of TPN171H:CL/F
Pharmacokinetic parameter of TPN171H:CL/F
Pharmacokinetic parameter of TPN171H:BRPP
Pharmacokinetic parameter of TPN171H:BRPP

Secondary Outcome Measures

Full Information

First Posted
June 21, 2023
Last Updated
October 17, 2023
Sponsor
Vigonvita Life Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT06090136
Brief Title
Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects
Official Title
A Study Evaluating Safety and Pharmacokinetics of a Single Oral TPN171H in Elderly Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
September 14, 2020 (Actual)
Primary Completion Date
December 14, 2020 (Actual)
Study Completion Date
July 22, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vigonvita Life Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
It is a single-center, open-label, Phase I clinical study evaluating the safety and pharmacokinetics of a single oral TPN171H in elderly subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erectile Dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TPN171H
Arm Type
Experimental
Arm Description
5 mg TPN171H tablets,single dose,oral
Intervention Type
Drug
Intervention Name(s)
TPN171H
Intervention Description
5 mg TPN171H tablets,single dose,oral
Primary Outcome Measure Information:
Title
Adverse events
Description
Number of Participants With treatment-related Adverse Events and Serious Adverse Events
Time Frame
7 days after dosing
Title
Pharmacokinetic parameter of TPN171H:Tmax
Description
Pharmacokinetic parameter of TPN171H:Tmax
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:Cmax
Description
Pharmacokinetic parameter of TPN171H:Cmax
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:T1/2
Description
Pharmacokinetic parameter of TPN171H:T1/2
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:AUC0-t
Description
Pharmacokinetic parameter of TPN171H:AUC0-t
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:AUC0-∞
Description
Pharmacokinetic parameter of TPN171H:AUC0-∞
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:AUC0-24h
Description
Pharmacokinetic parameter of TPN171H:AUC0-24h
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:Ke
Description
Pharmacokinetic parameter of TPN171H:Ke
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:Vd
Description
Pharmacokinetic parameter of TPN171H:Vd
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:MRT
Description
Pharmacokinetic parameter of TPN171H:MRT
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:CL/F
Description
Pharmacokinetic parameter of TPN171H:CL/F
Time Frame
48 hours after dosing
Title
Pharmacokinetic parameter of TPN171H:BRPP
Description
Pharmacokinetic parameter of TPN171H:BRPP
Time Frame
48 hours after dosing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: ≥ 65 years old; Male≥50kg,femal≥45kg, Body mass index should be between 18 and 30 kg/m2 (inclusive); No major organ dysfunction;normal heart, liver and kidney function; Physical examination, vital signs examination, laboratory examination (blood routine, urine routine, blood biochemistry), 12 lead ECG, Abdominal ultrasound, chest X-ray results were normal or abnormal but investigator judged suitable for participating in this trial; Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent Exclusion Criteria: Allergies to test preparations, any of their ingredients, and related preparations; With allergies or allergic diseases; Surgical condition or condition that may significantly affect ADME of the drug, urgical condition or condition that may pose a hazard if the subject participating in the study Myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass grafting, congestive heart failure, severe arrhythmias, cerebrovascular accidents, including transient ischemic attack within 3 months before inclusion; Taken any of drugs(Inhibits or induces liver metabolism) within 2 weeks before inclusion;administered with Nitrate/Nitric oxide (NO) donors。 With a history of the following ocular diseases: nonvascular anterior ischemic optic neuropathy (NAION), abnormal color vision, hereditary retinopathy (e.g. Retinitis pigmentosa), and macular degeneration; A history of sudden decrease or loss of hearing; A history of postural hypotension; Blood loss ≥400 mL within 3 months before inclusion; Participated in other drug clinical trials or medical devices clinical trials within 3 months before administration; Drink alcohol at least 2 times a day or more than 14 times a week in the 6 months prior to enrollment or alcoholics(Drink alcoholics defined as 125 mL of wine, 220 mL of beer, or liquor50mL; Alcoholism is defined as 5 or more drinks in approximately 2 hours) ; A history of drug use or have been screened positive for drug abuse; Smoked more than 10 cigarettes a day within 6 months prior to inclusion; hepatitis B surface antigen (HBsAg),hepatitis C virus antibody,treponema pallidum antibody,Human immunodeficiency virus antibody (HIV)positive; Other factors that the investigator considered inappropriate for the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gangyi Liu
Organizational Affiliation
Shanghai Xuhui Central Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shanghai Xuhui Central Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200031
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects

We'll reach out to this number within 24 hrs